Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2008 1
2009 2
2011 2
2013 2
2014 3
2015 4
2016 5
2017 4
2018 5
2019 10
2020 3
2021 6
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Benefit-risk evaluation: the past, present and future.
Juhaeri J. Juhaeri J. Ther Adv Drug Saf. 2019 Aug 26;10:2042098619871180. doi: 10.1177/2042098619871180. eCollection 2019. Ther Adv Drug Saf. 2019. PMID: 31489173 Free PMC article. Review.
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS, Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B, Beachler DC, Crowe CL, Johannes CB, Juhaeri J, Lanes S, Pan C, Rothman KJ, Saltus CW, Walsh KE. Anthony MS, et al. Among authors: juhaeri j. Diabetes Care. 2024 Apr 1;47(4):712-719. doi: 10.2337/dc23-1911. Diabetes Care. 2024. PMID: 38363873 Free PMC article.
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, Asiimwe A, Downey G, Genov G, Hermann R, Noel R, Peters R, Micaleff A, Tzoulaki I, Ashby D; PROTECT Benefit-Risk group. Hallgreen CE, et al. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):238-50. doi: 10.1002/pds.3880. Epub 2015 Nov 2. Pharmacoepidemiol Drug Saf. 2016. PMID: 26521865 Free article. Review.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants. Mt-Isa S, et al. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Pharmacoepidemiol Drug Saf. 2014. PMID: 24821575 Review.
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.
Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, Mol P, Levitan B, Huang HY, Coplan P, Li H; BRACE Special Interest Group. Radawski C, et al. Among authors: juhaeri j. Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1233-40. doi: 10.1002/pds.3859. Epub 2015 Oct 12. Pharmacoepidemiol Drug Saf. 2015. PMID: 26456379 Review.
Response to letter to the editor regarding "Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data".
Beachler DC, Taylor DH, Anthony MS, Yin R, Li L, Saltus CW, Li L, Shaunik A, Walsh KE, Rothman KJ, Johannes CB, Aroda VR, Carr W, Goldberg P, Accardi A, O'Shura JS, Sharma K, Juhaeri J, Lanes S, Wu C. Beachler DC, et al. Among authors: juhaeri j. Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):110-111. doi: 10.1002/pds.5376. Epub 2021 Oct 27. Pharmacoepidemiol Drug Saf. 2022. PMID: 34687257 No abstract available.
48 results